Cargando…
Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
Endocrine therapies are the main treatment strategies for the clinical management of hormone-dependent breast cancer. Despite prolonged time to recurrence in the adjuvant setting and the initial clinical responses in the metastatic setting, many patients eventually encounter tumour relapse due to ac...
Autores principales: | Alataki, Anastasia, Dowsett, Mitch |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254309/ https://www.ncbi.nlm.nih.gov/pubmed/35613334 http://dx.doi.org/10.1530/ERC-21-0293 |
Ejemplares similares
-
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer
por: Ribas, Ricardo, et al.
Publicado: (2018) -
Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
por: Shen, Le-Sang, et al.
Publicado: (2020) -
Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers
por: Ribas, Ricardo, et al.
Publicado: (2014) -
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
por: Migliaccio, Ilenia, et al.
Publicado: (2015) -
Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
por: Abdel-Razeq, Hikmat
Publicado: (2016)